This section highlights FDA-related milestones and regulatory updates for drugs developed by InflaRx (IFRX).
Over the past two years, InflaRx has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Izicopan, Vilobelimab, and INF904. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Izicopan FDA Regulatory Timeline and Events
Izicopan is a drug developed by InflaRx for the following indication: small molecule inhibitor of the C5a receptor (C5aR).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Izicopan
- Announced Date:
- November 6, 2026
- Indication:
- small molecule inhibitor of the C5a receptor (C5aR)
Announcement
InflaRx N.V. announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izicopan, formerly known as INF904, the Company’s orally administered, next-generation small molecule inhibitor of the C5a receptor (C5aR1).
Read Announcement- Drug:
- Izicopan
- Announced Date:
- November 3, 2026
- Indication:
- small molecule inhibitor of the C5a receptor (C5aR)
Announcement
InflaRx N.V today is presenting its clinical development strategy and commercial vision for izicopan at the Company’s Capital Markets Day.
Read Announcement- Drug:
- Izicopan
- Announced Date:
- October 22, 2026
- Indication:
- small molecule inhibitor of the C5a receptor (C5aR)
Announcement
InflaRx N.V announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25.
AI Summary
InflaRx N.V. presented new pre-clinical findings on izicopan at the American Society of Nephrology’s Kidney Week 2026 in Denver, held October 21–25. The oral drug was tested in two hamster models: ischemia–reperfusion injury, which models acute kidney injury, and ureteral obstruction, which models ongoing kidney damage and scarring. In both models, izicopan reduced signs of kidney injury compared with vehicle treatment.
In the acute injury model, a single dose lowered blood creatinine and blood urea nitrogen (BUN) and improved tissue damage scores. In the obstruction model, daily treatment for 14 days lowered BUN and improved kidney tissue scores; measures of fibrosis also showed a favorable trend, but the difference was not statistically significant. The results suggest that izicopan’s blocking of C5aR-driven inflammation may help protect the kidneys. Structural modeling also suggested that izicopan may have less interaction with certain drug-processing enzymes than avacopan. InflaRx said the findings support further study of izicopan for kidney diseases, including ANCA-associated vasculitis.
Read Announcement- Drug:
- Izicopan
- Announced Date:
- October 2, 2026
- Indication:
- small molecule inhibitor of the C5a receptor (C5aR)
Announcement
InflaRx N.V announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.
AI Summary
InflaRx N.V. announced that its research has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026. The meeting will take place in Denver, Colorado, from October 21 to 25. The poster is scheduled for October 22, from 10 a.m. to noon.
The presentation will describe izicopan, an oral drug that blocks the C5a receptor, and its potential in kidney disease models. InflaRx is developing izicopan for ANCA-associated vasculitis and other kidney conditions. The company says early clinical studies found the drug was generally well tolerated, with no safety concerns reported in the studies described. Phase 1 data also showed strong blocking of C5a-driven immune cell activity. Phase 2a results in other inflammatory conditions have shown encouraging signs, but the kidney-disease poster will focus on model research. The findings are early-stage and do not establish that izicopan is effective in patients with kidney disease.
Read Announcement
Vilobelimab FDA Regulatory Timeline and Events
Vilobelimab is a drug developed by InflaRx for the following indication: Pyoderma Gangraenosum.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Vilobelimab
- Announced Date:
- March 30, 2026
- Indication:
- Pyoderma Gangraenosum
Announcement
InflaRx N.V. announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum (PG) were featured in an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held March 27-31, 2026, in Denver, CO.
AI Summary
InflaRx N.V. announced that data from its Phase 3 study of vilobelimab in pyoderma gangrenosum (PG) were featured in an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting, held March 27–31, 2026, in Denver, CO. The company highlighted the presentation as a key opportunity to share late-stage results with dermatology experts and investigators attending the meeting.
The presented data showed encouraging signals of clinical activity across several measures: higher rates of complete remission, greater target ulcer closure, and meaningful reductions in ulcer volume versus placebo. Vilobelimab also produced a large reduction in C5a levels (mean change from baseline −76.6% versus −13.5% with placebo). The treatment was generally well tolerated, with most adverse events reported as mild to moderate and similar rates of serious adverse events between groups (6.3% with vilobelimab and 4.5% with placebo).
Read Announcement- Drug:
- Vilobelimab
- Announced Date:
- March 18, 2026
- Indication:
- Pyoderma Gangraenosum
Announcement
InflaRx N.V. announced an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The meeting will be held March 27-31, 2026, in Denver, CO.
AI Summary
InflaRx N.V. announced that data from its Phase 3 trial of vilobelimab for pyoderma gangrenosum (PG) will be presented orally as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, CO. The company said the Phase 3 multicenter, randomized, placebo-controlled results were selected for an oral session, highlighting progress in treating this rare, painful skin condition and the potential role of C5a/C5aR inhibition in chronic inflammatory diseases.
The late-breaking oral presentation, titled “Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial,” will be delivered by Benjamin Kaffenberger, MD, on March 28, 2026, from 2:24–2:36 PM MT in Bellco Theatre 3. Camilla Chong, InflaRx’s Chief Medical Officer, said it is an honor the data were selected and looks forward to engaging the dermatology community on these findings.
Read Announcement- Drug:
- Vilobelimab
- Announced Date:
- December 30, 2025
- Indication:
- Pyoderma Gangraenosum
Announcement
InflaRx N.V today outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum (PG), which was terminated earlier this year after an Independent Data Monitoring Committee (IDMC) recommended the trial be stopped early due to futility.
AI Summary
InflaRx reported multiple analyses of its Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG), which was stopped early after an Independent Data Monitoring Committee recommended termination for futility. The intent-to-treat analysis of 54 enrolled patients showed the primary endpoint—complete target ulcer closure on two consecutive visits—favored vilobelimab 20.8% versus placebo 16.7% (not significant). Key secondary outcomes also trended better with vilobelimab but were not statistically significant. Overall, the drug was well tolerated.
Post-hoc analyses found stronger signals: an MMRM for percent change in target ulcer volume showed an average benefit for vilobelimab (–45.4%, p=0.0428, Weeks 2–26 with LOCF), with significant differences from Week 14 to Week 26. ANCOVAs for mean percent change in volume (p=0.0111) and area (p=0.0072) also favored vilobelimab, suggesting longer treatment might improve outcomes. InflaRx says it will meet with the FDA to discuss a development path and would pursue further PG work with a partner.Read Announcement
- Drug:
- Vilobelimab
- Announced Date:
- May 28, 2025
- Indication:
- Pyoderma Gangraenosum
Announcement
InflaRx N.V. announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility.
AI Summary
InflaRx N.V. announced that the Independent Data Monitoring Committee (IDMC) recommended stopping its Phase 3 trial for vilobelimab in treating pyoderma gangrenosum (PG) due to futility. The decision came from an unblinded interim analysis of data from the first 30 patients enrolled in the study. Although the committee found no unexpected adverse events, the early evidence indicated that the treatment was unlikely to provide the intended benefit. As a result, InflaRx will discontinue further development of vilobelimab for PG and focus on other projects, such as advancing its oral inhibitor INF904 for chronic immune-dermatological conditions. The company expressed gratitude to the participating physicians and patients for their commitment to the study, underscoring its ongoing commitment to developing innovative therapies for underserved patient populations.
Read Announcement - Drug:
- Vilobelimab
- Announced Date:
- March 7, 2025
- Indication:
- Pyoderma Gangraenosum
Announcement
InflaRx N.V announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses.
AI Summary
InflaRx N.V. announced that it is showcasing several posters at the 2025 American Academy of Dermatology Annual Meeting in Orlando, FL. These presentations focus on vilobelimab’s potential in treating pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS). The posters include clinical efficacy data, safety evaluations, and detailed pharmacokinetic (PK) and pharmacodynamic (PD) analyses that highlight the drug’s role in reducing inflammation.
Data from the studies show that vilobelimab is well tolerated among patients suffering from these conditions and is effective in lowering C5a—a key factor in the inflammatory process. In HS patients, promising improvements were observed, such as a significant reduction in draining tunnels. These findings support the idea that targeting the C5a/C5aR pathway may be beneficial in managing these challenging, inflammation-driven diseases and indicate that further research into vilobelimab could lead to promising treatment options.
Read Announcement- Drug:
- Vilobelimab
- Announced Date:
- January 15, 2025
- Indication:
- Pyoderma Gangraenosum
Announcement
InflaRx N.V announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) with or without extracorporeal membrane oxygenation (ECMO).
AI Summary
InflaRx N.V. announced that the European Commission has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab). This new approval is for treating adult patients with SARS‑CoV‑2-induced acute respiratory distress syndrome (ARDS). The authorized use applies to those receiving systemic corticosteroids as part of standard care while on invasive mechanical ventilation, with or without extracorporeal membrane oxygenation (ECMO).
GOHIBIC is now the first and only treatment approved in the European Union for SARS‑CoV‑2-induced ARDS. The decision follows positive results from the PANAMO study, a large Phase 3 trial that showed improved survival rates among patients. The approval is valid across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway, marking a significant advancement in the treatment options available for critically ill COVID-19 patients.
Read Announcement
INF904 FDA Regulatory Events
INF904 is a drug developed by InflaRx for the following indication: C5aR Inhibitor.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- INF904
- Announced Date:
- November 10, 2025
- Indication:
- C5aR Inhibitor
Announcement
InflaRx N.V announced positive topline data from a Phase 2a basket study exploring INF904 in HS and CSU. Efficacy data were reported from 29 of 31 HS patients and from 30 of 31 CSU patients.
AI Summary
InflaRx N.V. announced positive topline data from a Phase 2a basket study of oral C5aR inhibitor INF904 in patients with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). Efficacy data were reported from 29 of 31 HS patients and from 30 of 31 CSU patients, signaling promising activity for the oral C5a receptor blocker in both inflammatory skin diseases.
The company said it will discuss these topline results on a webcast and conference call on Monday, November 10 at 8:00 AM EST / 2:00 PM CET, with a slide presentation and key opinion leader commentary. Participants can pre-register to receive the invite link and dial-in details, and a replay will be available on InflaRx’s website.
InflaRx also expects to publish its third quarter 2025 financial results the same day in a pre‑market release.
Read Announcement- Drug:
- INF904
- Announced Date:
- December 20, 2024
- Indication:
- C5aR Inhibitor
Announcement
InflaRx N.V announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company's oral C5aR inhibitor, INF904.
AI Summary
InflaRx N.V. announced that the first patient has been dosed in its Phase 2a basket study using its oral C5aR inhibitor, INF904. This clinical trial is testing the treatment for two inflammatory conditions: chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS). The study is designed to evaluate the safety, drug levels, and early signs of clinical benefit of INF904.
In this multi-center, open-label trial, approximately 75 patients with moderate-to-severe CSU or HS will participate. The treatment phase will last four weeks, followed by an additional four-week follow-up period. The trial will test various dosing regimens to identify the best exposure, with data expected later next year. InflaRx believes that INF904’s anti-inflammatory properties and best-in-class potential could address significant unmet medical needs in these conditions and possibly other immune-inflammatory disorders.
Read Announcement